The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. - Wikidata - wikimedia - TriplyDB

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

http://www.wikidata.org/entity/Q34196658

about

Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress Emergent treatments based on the pathophysiology of bipolar disorder: A selective review Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders Cardiometabolic Health in Bipolar Disorder Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania.A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.Characterizing N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) binding for lead poisoning treatment A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression Antioxidants as potential therapeutics for neuropsychiatric disorders.Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.Management of obsessive-compulsive disorder comorbid with bipolar disorder.Oxidative stress and psychological disorders.New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.Glutamate-based anxiolytic ligands in clinical trials.N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review.The glutathione system: a new drug target in neuroimmune disorders.Drugs under early investigation for the treatment of bipolar disorder.The renin-angiotensin system: a possible new target for depression.Psychopharmacological interventions in autism spectrum disorder.Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor.Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.Oxidative Stress and the Central Nervous System.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats.Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy.Guidelines for the recognition and management of mixed depression.N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in Adolescents: An Open-Label Pilot Study.Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications.Immune-based strategies for mood disorders: facts and challenges.A potential role for N-acetylcysteine in the management of methamphetamine dependence.The use of magnetic resonance spectroscopy for assessing the effect of diet on cognition.Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.Mitochondrial Agents for Bipolar Disorder.[Pharmaceutical treatment of bipolar depression. Evidence from clinical guidelines and treatment recommendations].N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence

P2860

Q27022219-AA473E8A-4543-4AF1-ACBA-00B90D5732AC Q28082445-F30D1620-511B-46EC-A5F8-288A216A485A Q28709645-420EEE04-239D-477F-9B62-9047B8177116 Q33795131-D527A0C9-9A8F-4A10-9BF2-D0284984AFDB Q34379367-B5876901-82B5-4C47-9A38-C2685C3473A2 Q34473631-C9CA31D8-D182-4C1F-BBB1-FF031642E084 Q34543171-86751575-5BD7-49FD-971D-76ADDB29DC4E Q34649372-3CFFC760-E41B-47B3-91D6-CDACEB838BF5 Q34865641-4636E759-1EDA-4FF2-8162-A9F8B82CBC56 Q35928836-3F41217E-6D8A-4F6F-98AD-35A3FEA66CF5 Q36424640-AF08A3EF-39B5-4013-852F-68700CEE307E Q36736055-7A83C5A6-E88C-499D-9469-FEABBAA0C9D0 Q37349910-C7346DA7-52AA-460F-B4CA-0BF6C8A5A2D2 Q37400532-28B68424-AEF8-4CEB-A77A-9C2B9ED77DFB Q37661360-11D04CEC-FED8-4A59-87E4-D41D82A07C77 Q37978196-48A6B868-BCA6-40B4-A25A-33A48236F796 Q38110306-6F7904C9-75FD-426D-80A1-DF568F9AA30D Q38175882-6A9A4868-D1DD-43EF-884F-2F5509BE9C59 Q38206126-EC663D03-1420-4986-823C-1D29B6883778 Q38364032-1CA339A0-5605-4789-89C2-4A7AD3EDDA5A Q38651269-2BE866C1-5FD5-49EF-B870-B1F5B3892502 Q38739577-9967A339-4BE1-4151-B751-17D5EA1DFAD6 Q38742940-A297A8A3-E51B-44E5-84D9-62C70397A2BD Q38779572-E30C3092-968B-4FCA-BED0-B4068E97FDFB Q38984077-5081D9FC-1E78-4811-A5E8-BF1FFED89AEF Q38990885-74FA8E89-F9C8-4586-85F8-2D7445728B39 Q44142664-F0B4D4ED-BAF0-4293-BEF5-982F95E6A4FC Q46017960-86C9080D-724D-40D1-A0A3-B01A2D03529E Q46070016-2F9B09BC-2B84-43FE-AD0B-21FFA3798449 Q46300154-98FBD936-8898-4460-95BD-257DA362903A Q47275184-69FD321A-B96B-42AC-B6D2-92A983046681 Q47667767-6B538D95-5F5D-46CB-BE0F-6F193B29764C Q47694934-824DDEA3-7786-477D-9500-E086AB40D1B5 Q48013273-74D5ACBA-5B02-4E0D-9D67-C3853B12BB48 Q48091363-4D27110B-6F10-4087-8BF5-2CB1D34ACF95 Q48195966-CC912D7D-1B97-44D9-BB0C-6567A171AA18 Q52621890-CDF8E8D0-124D-4023-8F4D-DF875BC97437 Q52881994-8F8C95EC-6709-4AF0-B195-36EC2EC8E429 Q58698161-E6973A62-E9B2-4A86-850F-FB1138739D4D

P2860

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

http://www.wikidata.org/entity/Q34196658

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The efficacy of N-acetylcystei ...... pression: an open label trial.

@ast

The efficacy of N-acetylcystei ...... pression: an open label trial.

@en

The efficacy of N-acetylcystei ...... pression: an open label trial.

@nl

type

label

The efficacy of N-acetylcystei ...... pression: an open label trial.

@ast

The efficacy of N-acetylcystei ...... pression: an open label trial.

@en

The efficacy of N-acetylcystei ...... pression: an open label trial.

@nl

prefLabel

The efficacy of N-acetylcystei ...... pression: an open label trial.

@ast

The efficacy of N-acetylcystei ...... pression: an open label trial.

@en

The efficacy of N-acetylcystei ...... pression: an open label trial.

@nl

P1433

Q34196658-D2EA2A71-39F5-4F64-9CA7-44E6115DD140

P1476

Q34196658-D6897D46-25B4-47EE-8BF5-A6901C9E47C8

P2093

Q34196658-12625621-2E6A-4CA8-A38A-7D29889C47CC

Q34196658-1D52B1CF-2265-4BB1-97D3-FBF724415306

Q34196658-71B1E988-5188-4283-A88D-C48BB528B403

Q34196658-75003DF6-DAF2-4D37-BBC1-CAF8169D724E

Q34196658-99E5B1A8-5718-4126-A434-0F81F406FB9E

Q34196658-A32B58B9-CF44-4F33-A074-85525ACF627A

Q34196658-B7B701B4-E8A9-41AE-9B19-77575F70F526

Q34196658-D0DD5D17-210E-495F-BC58-A1D6DDBF6FDB

Q34196658-E5081106-AE7C-433B-AFE9-225418AF8C28

P304

Q34196658-4F36868E-916D-4DAB-AAE8-4453C170FF2A

P31

Q34196658-20B22220-FA5B-44EB-BC1D-A2C7EF158660

P356

Q34196658-D732039E-B849-4CB1-AC26-3B8C3C2202E0

P433

Q34196658-862923BB-9631-48E3-8D28-4093B7F2F4AF

P478

Q34196658-A8DC3AA7-1BA6-4ACA-9388-1C7E06546284

P50

Q34196658-16882189-C67B-4D0C-84E7-EE9496A6000D

Q34196658-654D63CC-E234-431F-8DE9-DF4C23519CFE

Q34196658-9CB5C6E8-6B89-4526-A92A-F14D1D00A365

Q34196658-B9857F7E-42E4-4A39-A489-6979D32B1D27

Q34196658-D7CB910D-E590-44F4-B0BE-DE5BDF118E34

Q34196658-D84B8D18-D36E-4718-A035-4A7442B12249

P577

Q34196658-E0041F1E-0749-4760-8DC1-ABAA9DD92F17

P5875

Q34196658-1203264E-C782-4FA2-989F-12592940BDA1

P698

Q34196658-E9D0F64F-C7DD-45A2-AB3D-D3C9B42B9354

P356

J.JAD.2011.06.005

P1433

Journal of Affective Disorders

P1476

The efficacy of N-acetylcystei ...... pression: an open label trial.

@en

P2093

Christine Allwang

http://www.w3.org/2001/XMLSchema#string

Gin S Malhi

http://www.w3.org/2001/XMLSchema#string

Heidi Cobb

http://www.w3.org/2001/XMLSchema#string

Ian Schapkaitz

http://www.w3.org/2001/XMLSchema#string

Karen Hewitt

http://www.w3.org/2001/XMLSchema#string

Kristy Kohlmann

http://www.w3.org/2001/XMLSchema#string

Olivia Dean

http://www.w3.org/2001/XMLSchema#string

Seetal Dodd

http://www.w3.org/2001/XMLSchema#string

Susan Jeavons

http://www.w3.org/2001/XMLSchema#string

P304

389-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAD.2011.06.005

http://www.w3.org/2001/XMLSchema#string

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Brisa S. Fernandes

Flávio Kapczinski

Clarissa Severino Gama

P577

2011-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51457606

http://www.w3.org/2001/XMLSchema#string

P698

21719110

http://www.w3.org/2001/XMLSchema#string